Form 4: Day One Biopharmaceuticals Executive Samuel Blackman Sells 20,000 Shares

Samuel Blackman, Head of R&D at Day One Biopharmaceuticals, sold 20,000 shares of common stock at an average price of $16.1083 on February 27, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On February 27, 2024, Samuel C. Blackman, Head of R&D at Day One Biopharmaceuticals, sold 20,000 shares of the company's common stock.
• The sales were executed at a weighted average price of $16.1083 per share, with individual transactions ranging from $16.00 to $16.38.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted on October 10, 2023.
• Following the transaction, Blackman directly owns 1,224,662 shares of Day One Biopharmaceuticals' common stock.
• Blackman also indirectly owns 1,000,000 shares through the 2021 Blackman Family LLC, but disclaims beneficial ownership except to the extent of his and his wife's pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting an insider stock sale. It doesn't inherently convey positive or negative sentiment, as it's a factual disclosure.

Industry Context

Insider sales are a common occurrence in publicly traded companies. They can be driven by various factors, including personal financial planning and diversification. The use of a pre-arranged Rule 10b5-1 trading plan suggests that the sales were planned in advance and not based on any material non-public information.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment, although the use of a 10b5-1 plan mitigates concerns about insider information.

Key Dates